Ribavirin in respiratory syncytial virus infection.

Ribavirin in respiratory syncytial virus infection

At a recent workshop on infection the indications for ribavirin were discussed. Ribavirin has recently been licensed for hospital use in the United Kingdom having previously been available only on a named patient basis. Nebulised ribavirin is being vigorously promoted by the United Kingdom marketing company, Brittania Pharmaceuticals, for selected use in respiratory syncytial virus infections l...

Ribavirin for respiratory syncytial virus infection.

Over the winter of 1988, 10 infants with congenital heart disease were treated for severe bronchiolitis at Guy's Hospital. All required respiratory support of greater than 50% oxygen in a headbox, and seven required assisted ventilation. Seven patients were positive for respiratory syncytial virus, and seven received nebulised ribavirin for three to five days. There were four deaths, all infant...

Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview.

OBJECTIVE To systematically review the evidence evaluating the efficacy of aerosolized ribavirin for the treatment of infants with respiratory syncytial virus lower respiratory tract infection. DESIGN A computerized search of MEDLINE from 1975 to the present, a review of the reference lists of each retrieved article, and contact with experts. PATIENTS infants with documented respiratory syn...

Bovine respiratory syncytial virus infection.

Bovine respiratory syncytial virus (BRSV) belongs to the pneumovirus genus within the family Paramyxoviridae and is a major cause of respiratory disease in young calves. BRSV is enveloped and contains a negative sense, single-stranded RNA genome encoding 11 proteins. The virus replicates predominantly in ciliated respiratory epithelial cells but also in type II pneumocytes. It appears to cause ...

Respiratory Syncytial Virus (RSV) Infection